Trellis Bioscience, Inc.

Trellis Bioscience, Inc. is a US-based biopharmaceutical company focused on developing monoclonal antibody therapies that target infectious diseases, particularly prosthetic joint infections, respiratory syncytial virus, and human cytomegalovirus. Founded in 1998 and headquartered in Redwood City, US, Trellis Bioscience specializes in monoclonal antibody therapy development. The company has undergone strategic shifts to focus on infectious diseases and has successfully raised USD 11.

40 mn through various funding rounds, with the latest funding round being a Grant of USD 3. 20 mn from CARB-X on October 22, 2024. The company was founded by Larry Kauvar and Stote Ellsworth, with CEO Stefan Ryser currently at the helm. Trellis Bioscience specializes in developing innovative monoclonal antibody (mAb) therapies targeting infectious diseases.

Its lead product, TRL1068 (calpurbatug), is currently in Phase 1 clinical trials. The company utilizes its proprietary CellSpot™ platform for rapid discovery of high-affinity mAbs from human memory B-cells, enhancing therapeutic efficacy. Its product pipeline addresses viral infections caused by HCMV, RSV, and influenza, catering to global health markets. Trellis Bioscience generates revenue primarily through partnerships and collaborations in the biopharmaceutical sector, focusing on clinical studies and the development of monoclonal antibody therapies.

The company engages in transactions with pharmaceutical companies and healthcare institutions for research and development initiatives. Revenue is also derived from agreements related to its CellSpot™ technology. Specific pricing details are not disclosed, but transactions align with industry standards, involving clinical development milestones and potential royalties from successful mAb commercialization. Moving forward, Trellis Bioscience aims to enhance its clinical study advancements with the recent funding raised from Nodenza Venture Partners.

This funding will support ongoing clinical trials and further development of new monoclonal antibody therapies. The company is also exploring expansion into new markets, focusing on regions heavily affected by infectious diseases, with plans to launch additional products as they progress through various trial phases.